Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review
Temozolomide (TMZ) is an alkylating chemotherapeutic agent that has recently been used in some cases as a new therapeutic tool for pituitary carcinomas and aggressive pituitary adenomas. In this report, we present the case of effective TMZ treatment in a 42-year-old man with ACTH-secreting carcinoma...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/tsw.2010.210 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850178684815671296 |
|---|---|
| author | Lorenzo Curtò Maria L. Torre Francesco Ferraù Vincenzo Pitini Giuseppe Altavilla Francesca Granata Marcello Longo Leo J. Hofland Francesco Trimarchi Salvatore Cannavò |
| author_facet | Lorenzo Curtò Maria L. Torre Francesco Ferraù Vincenzo Pitini Giuseppe Altavilla Francesca Granata Marcello Longo Leo J. Hofland Francesco Trimarchi Salvatore Cannavò |
| author_sort | Lorenzo Curtò |
| collection | DOAJ |
| description | Temozolomide (TMZ) is an alkylating chemotherapeutic agent that has recently been used in some cases as a new therapeutic tool for pituitary carcinomas and aggressive pituitary adenomas. In this report, we present the case of effective TMZ treatment in a 42-year-old man with ACTH-secreting carcinoma. The tumor grew progressively over 4 years, from 2.2 to 31.1 cm3, despite three surgical approaches and gamma-knife treatment. Ki-67 increased from 2 to 18%. An intradural metastasis at the foramen magnum was detected by MRI after the third operation. Thereafter, four cycles of 5-day TMZ administration (200 mg/m2/day during the first, and 150 mg/m2/day during the following cycles) induced dramatic tumor size reduction (>90%). Clinical conditions improved progressively and, after 17 months from the beginning of TMZ administration, the patient is still alive. The treatment was well tolerated except for a transient thrombocytopenia (grade 4 WHO). |
| format | Article |
| id | doaj-art-c624614253dd4e9da55e866ec4084459 |
| institution | OA Journals |
| issn | 1537-744X |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-c624614253dd4e9da55e866ec40844592025-08-20T02:18:39ZengWileyThe Scientific World Journal1537-744X2010-01-01102132213810.1100/tsw.2010.210Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature ReviewLorenzo Curtò0Maria L. Torre1Francesco Ferraù2Vincenzo Pitini3Giuseppe Altavilla4Francesca Granata5Marcello Longo6Leo J. Hofland7Francesco Trimarchi8Salvatore Cannavò9Department of Medicine and Pharmacology, Section of Endocrinology, University of Messina, ItalyDepartment of Medicine and Pharmacology, Section of Endocrinology, University of Messina, ItalyDepartment of Medicine and Pharmacology, Section of Endocrinology, University of Messina, ItalyDepartment of Medical Oncology, University of Messina, ItalyDepartment of Medical Oncology, University of Messina, ItalyDepartment of Radiological Sciences, University of Messina, ItalyDepartment of Radiological Sciences, University of Messina, ItalyDepartment of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The NetherlandsDepartment of Medicine and Pharmacology, Section of Endocrinology, University of Messina, ItalyDepartment of Medicine and Pharmacology, Section of Endocrinology, University of Messina, ItalyTemozolomide (TMZ) is an alkylating chemotherapeutic agent that has recently been used in some cases as a new therapeutic tool for pituitary carcinomas and aggressive pituitary adenomas. In this report, we present the case of effective TMZ treatment in a 42-year-old man with ACTH-secreting carcinoma. The tumor grew progressively over 4 years, from 2.2 to 31.1 cm3, despite three surgical approaches and gamma-knife treatment. Ki-67 increased from 2 to 18%. An intradural metastasis at the foramen magnum was detected by MRI after the third operation. Thereafter, four cycles of 5-day TMZ administration (200 mg/m2/day during the first, and 150 mg/m2/day during the following cycles) induced dramatic tumor size reduction (>90%). Clinical conditions improved progressively and, after 17 months from the beginning of TMZ administration, the patient is still alive. The treatment was well tolerated except for a transient thrombocytopenia (grade 4 WHO).http://dx.doi.org/10.1100/tsw.2010.210 |
| spellingShingle | Lorenzo Curtò Maria L. Torre Francesco Ferraù Vincenzo Pitini Giuseppe Altavilla Francesca Granata Marcello Longo Leo J. Hofland Francesco Trimarchi Salvatore Cannavò Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review The Scientific World Journal |
| title | Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review |
| title_full | Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review |
| title_fullStr | Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review |
| title_full_unstemmed | Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review |
| title_short | Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review |
| title_sort | temozolomide induced shrinkage of a pituitary carcinoma causing cushing s disease report of a case and literature review |
| url | http://dx.doi.org/10.1100/tsw.2010.210 |
| work_keys_str_mv | AT lorenzocurto temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview AT marialtorre temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview AT francescoferrau temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview AT vincenzopitini temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview AT giuseppealtavilla temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview AT francescagranata temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview AT marcellolongo temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview AT leojhofland temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview AT francescotrimarchi temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview AT salvatorecannavo temozolomideinducedshrinkageofapituitarycarcinomacausingcushingsdiseasereportofacaseandliteraturereview |